Abstract Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication noncompliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de).
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Introduction
The Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the treatment of plaque psoriasis. The full version of the Guidelines has been published in the Journal der Deutschen Dermatologischen Gesellschaft (JDDG 2006 Suppl 2) and is available at http://www.psoriasis-leitlinie.de [149] . This article summarizes the key points of the Guidelines.
Background
Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries is 1.5-2% [2] . Studies on the impairment of life quality have shown that, depending on the severity of the disease, a significant burden may exist in the form of a disability or psychosocial stigmatization [3] . Patient surveys have shown that the mental and physical impairment associated with psoriasis is comparable to that of other significant chronic conditions, such as type 2 diabetes or chronic respiratory diseases [4] .
Patient surveys have shown that only 25% of psoriasis patients are highly satisfied with the outcome of their treatment, another 50% indicate moderate satisfaction, and approximately 20% report low treatment satisfaction [5] . In addition, there is a high non-compliance rate in the intake of medication of up to 40% [1] .
Experience has shown that treatment selection for patients with psoriasis vulgaris is more commonly based on traditional concepts than on evidence-based data on the efficacy of various therapeutic options. In addition, it appears that systemic therapies are occasionally not applied in situations where they are needed due to the increased effort involved in monitoring the patients for unwanted side effects and possible interactions with other drugs.
Goal of the Guidelines
The overall objective of the Guidelines is to provide dermatologists in clinics and private practice with an accepted and evidence-based decision-making tool for the selection and implementation of a suitable and efficacious treatment for patients with psoriasis vulgaris. The focus of the Guidelines is on the induction therapy of mild, moderate, and severe plaque-type psoriasis in adults.
1. Physicians' personal experiences and traditional therapeutic concepts should be supplemented and, if necessary, replaced by an evidence-based assessment of the efficacy of individual therapies in psoriasis vulgaris. 2. The guidelines provide in-depth explanations of the available systemic and topical treatments for psoriasis, including the different photo-and photochemical therapies, and provide detailed descriptions of the administration and safety aspects.
I. Kopp Ständige Kommission Leitlinien der AWMF, c/o Philipps-Universität Marburg, 3 . By providing background information on the profile of the available drugs, including efficacy, safety, and aspects of practicality and costs, the Guidelines should facilitate the process of selecting an appropriate treatment for each individual patient. This should help increase compliance and optimize the benefit/risk ratio of psoriasis therapies.
Methods
A detailed description of the methodology employed in developing the Guidelines can be found in the Method Report on the Guidelines (http://www.psoriasis-leitlinie.de).
Basis of data
A systematic search of the literature was carried out in May 2005 with the objective of assessing the effectiveness of individual therapeutic options. This search yielded 6,224 publications of which 142 studies fulfilled the inclusion criteria for the Guidelines (see Box 1) and were therefore included in the assessment of the effectiveness of the relevant treatment. Various other aspects were evaluated on the basis of information presented in available literature, without a systematic analysis, and the years of personal experience of the experts. 
Evidence assessment
The efficacy and effectiveness of each intervention was evaluated using evidence-based criteria. The methodological quality of each individual study was assessed using the following grades of evidence (GE):
A 1 Meta-analysis that includes at least one randomized study with grade A 2 evidence. In addition, the results of the different studies included in the meta-analysis must be consistent with one another. A 2 A high-quality (e.g. sample-size calculation, flow chart, intention-to-treat (ITT) analysis, sufficient size) randomized, double-blind comparative clinical study. B
Randomized clinical study of lesser quality or other comparative study (non-randomized, cohort, or casecontrol study). 
Passages requiring consensus
The Guidelines Group defined particularly relevant sections as passages requiring consensus and approved these in the framework of the consensus conferences. These sections are highlighted in grey boxes.
Therapeutic recommendation
A distinct rating of the therapeutic options or a strict clinical algorithm cannot be defined for the treatment of psoriasis vulgaris. The criteria for selecting a particular therapy are complex. The decision for a specific treatment should be based on the profile of the available drugs and the characteristics of a given patient. The decision for or against a therapy remains a case-by-case decision. These Guidelines provide a reasonable form of assistance in deciding on a suitable therapy and are an instrument for optimizing the required therapeutic process.
The recommendations formulated in the text are supported graphically in selected key recommendations by the following indications of the strength of the therapeutic recommendation:
››
Measure is highly recommended › Measure is recommended fi Neutral fl Measure is not recommended flfl Measure is highly inadvisable
The strength of the recommendation reflects both a treatment's efficacy and the level of evidence supporting it as well as aspects of safety, practicality, and the cost/ benefit ratio. A consensus on the strength of the recommendation was reached during the Consensus Conference.
Results
Therapeutic options are named and discussed in alphabetical order. Fig. 1 Overview of the therapeutic options evaluated for chronic plaque psoriasis (the therapeutic options are listed alphabetically and do not represent a ranking)
Therapeutic strategies

Evaluation of topical and systemic therapies in tabular form
These tables are intended to provide a rough orientation for evaluating the therapeutic options. Cumulative calculations of the individual aspects for the overall evaluation of the therapeutic options are not possible and cannot be drawn upon for the final analysis of a therapeutic option. The product assessment for each individual patient may deviate greatly. A direct comparison between systemic and topical therapies is not possible because of the different severity of the psoriasis lesions of patients treated with topical or systemic treatments. The evaluations reported here were made on the basis of data extracted from the literature and expert opinions.
For further details refer to the Methods Report at www.psoriasis-leitlinie.de
Topical monotherapy
T h e ra p y E ff ic a c y L e v e l o f e v id e n c e S a fe ty /T o le r a n c e in in d u c ti o n th e ra p y S a fe ty /T o le ra n c e in m a in te n a n c e th e ra p y P ra c ti c a li ty (p a ti e n t) P ra c ti c a li ty (p h y s ic ia n )
C o s t/ B e n e fi t The evidence level applies only to the estimate of efficacy.
(b) Safety/tolerance in induction therapy or maintenance therapy This refers to the risk of occurrence of severe adverse drug reactions or the probability of adverse drug reactions that would result in the discontinuation of therapy.
(c) Practicality (Patient) This evaluation analyzes the effort involved in handling and administrating the treatment regimen by the patient.
(d) Practicality (Physician) This aspect considers the amount of work (documentation, explanation, monitoring), personnel and equipment needs, time for physician/patient interaction, remuneration of therapeutic measures, invoicing difficulties/risk of recourse claims from the health insurance companies.
(e) Cost/benefit Consideration of the costs of an induction therapy or a maintenance therapy.
The evaluations of safety/tolerance in induction therapy or maintenance therapy as well as practicality for the physician or patient and the cost/benefit were performed using a scale ranging from poor (-) to good (++++). The gradation between these two extremes was made based on expert opinion and unsystematic literature search. A level of evidence was not given for these evaluations since no systematic literature review was performed. 
Evaluation of topical therapies
Calcineurin inhibitors
General assessment
Of the three studies with topical calcineurin inhibitors (pimecrolimus, tacrolimus) assessed, one study met the inclusion criteria of the Guidelines. [6] For that reason, the efficacy of psoriasis vulgaris treatment with topical calcineurin inhibitors can currently only be rated with a level of evidence of 4. Based on the studies to date, there is no evidence that monotherapy with calcineurin inhibitors is beneficial. Other studies have, however, demonstrated that topical calcineurin inhibitors can be beneficial in the treatment of psoriasis vulgaris in corticosteroid-sensitive areas such as the face, intertriginous areas, and the anogenital region. Since topical calcineurin inhibitors are not approved treatment for psoriasis vulgaris, treatment may only be performed in off-label use. The tolerance is generally good. Data on long-term safety are not available due to the relatively short-period of availability. Broad usage as a first-line therapy does not appear to be justified by the existing data.
Therapeutic recommendation
Pimecrolimus and tacrolimus administered topically 1× to 2× per day can be considered to be a reasonable supplementary treatment of psoriasis vulgaris at specific locations of the body, such as the face, intertriginous areas and anogenital region (e.g. in interval therapy) or as a replacement for topical corticosteroids.
Watch for unwanted side effects such as burning and skin irritations.
Use at other body sites is not recommended. 
Corticosteroids
General assessment
Of the 100 studies assessed for a monotherapy with corticosteroids, 20 fulfilled the Guidelines' inclusion criteria. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] With the application of potent corticosteroids (betamethasone dipropionate, 2× daily), 46 There are no severe adverse drug reactions in the induction phase. Care must be taken regarding the development of typical adverse corticosteroid effects such as skin atrophies or teleangiectases in cases of longer application and in particularly sensitive areas. The practicality for physicians and patients is good.
Therapeutic recommendation
Therapy with topical corticosteroids is highly recommended for mild to moderate psoriasis vulgaris as a combination therapy with systemic therapies or other topical therapies.
The selection of the class of corticosteroids must be adjusted for the specific skin area to be treated. 
Coal tar
General assessment
Of 19 studies assessed, four fulfilled the Guidelines' inclusion criteria. [37] [38] [39] [40] Since only one monotherapy study was evaluated (with three patients), it is not possible to make a clear statement about the efficacy of monotherapy (LE 4). Coal tar is used in clinical studies in combination with phototherapy. In the combination therapy with UV light, a reduction of the PASI by about 75% was achieved in 45-80% of study participants after 15-20 applications. The additional effect of coal tar in combination therapy with UV compared to UV therapy alone has not been proven. The acceptance of coal tar is low due to its color and odor. Magistral preparations may be less expensive than comparable manufactured products.
Therapeutic recommendation
The efficacy of coal tar treatment in psoriasis vulgaris has not been demonstrated, either as monotherapy or combination therapy. For this reason, coal tar is not recommended for this indication.
In view of the low-risk and more practical therapeutic alternatives, a monotherapy of psoriasis vulgaris with coal tar is obsolete.
Only after careful consideration of the therapeutic benefit and after low-risk therapeutic alternatives have failed should coal tar be used in combination with UVB in exceptional refractory cases of psoriasis vulgaris Arch Dermatol Res (2007) 299: 111-138 117 Dithranol 
General assessment
Of 63 studies assessed for a monotherapy with dithranol, 11 fulfilled the Guidelines' inclusion criteria. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The results of the studies assessed showed total remission (PASI reduction 100%) in 30-70% of the patients and partial remission (PASI reduction 75%) in 26-100% of patients after 5-8 weeks of treatment (LE 2). The efficacy can be increased further if either calcipotriol creams or a UVB phototherapy is combined with dithranol. Dithranol, one of the oldest topical therapeutics for psoriasis vulgaris, is still a treatment for mild to moderate psoriasis vulgaris as an out-patient monotherapy and as part of combination therapies for moderate psoriasis vulgaris in hospitalized and day clinic patients. The therapy is very safe. Although skin irritations, burning, erythema and intermittent brown discolorations are observed, there are no systemic adverse drug reactions. The practicality is clearly limited for outpatient use. The practicality for the physician, especially when treating inpatients, and the costbenefit ratio are positive.
Therapeutic recommendation
Monotherapy for patients with mild and moderate psoriasis vulgaris is recommended for induction therapy during hospitalization
And conditionally recommended as an outpatient treatment.
Because it is more practical, short-contact therapy should be given preference. In hospitalized patients, classical dithranol therapy with 2× daily application without immediate rinsing can be easily performed.
The therapy should be performed for 4 and conditionally recommended as an outpatient treatment for 4-8 weeks.
Maintenance or long-term therapy with dithranol is not practical and offers no advantages.
In the treatment of severe forms of psoriasis vulgaris, combination treatment with phototherapy or other topical preparations (calcipotriol) is recommended because of the improved response rate. 
Tazarotene
Important drug interactions
Avoid concomitant use of preparations with irritating and drying properties
Other -
General assessment
Of the nine studies assessed, six fulfilled the Guidelines' inclusion criteria. [41] [42] [43] [44] [45] [46] After daily treatment with tazarotene 0.1%, approximately 50% of the patients showed at least a 50% improvement of the skin lesions after about 12 weeks of treatment (LE 2). An optimization of the therapeutic success and a reduction of the frequent skin irritations can be attained with a combination of tazarotene and topical corticosteroids. There are no severe adverse drug reactions. However, contact with healthy skin should be avoided to prevent skin irritation.
Therapeutic recommendation
The topical application of tazarotene is recommended for the treatment of mild to moderate psoriasis vulgaris.
An application of tazarotene in the evening in combination with a corticosteroid in the morning is recommended as a combination therapy to reduce irritation and increase efficacy.
Vitamin D 3 and analogues 
General assessment
Of the 39 studies considered, 11 fulfilled the Guidelines' inclusion criteria. [14, [22] [23] [24] [25] [47] [48] [49] [50] [51] [52] The majority of available data is on calcipotriol. After vitamin D 3 -analogue treatment of mild to moderate psoriasis vulgaris, 30-50% of the patients showed a marked improvement or clearance of the skin lesions within a few weeks (LE 1). The efficacy and tolerance can be further improved if the Vitamin D 3 -analogue is combined with topical corticosteroids during the initial therapy.
In the treatment of severely affected patients, topical therapy with vitamin D 3 -analogues demonstrated synergistic effects with a UV phototherapy and systemic cyclosporine therapy. The topical vitamin D 3 -analogues are generally well-tolerated and practicable for the physician and the patient. Temporary skin irritations may limit the use, especially on the face or the intertriginous areas.
Therapeutic recommendation
Vitamin D 3 -analogues are the treatment of choice, especially for maintenance therapy in mild to moderate psoriasis vulgaris.
On the basis of the extensive study data and the superior efficacy, this recommendation is particularly true for calcipotriol. Because of its low irritating potential, the application of tacalcitol is particularly recommended for sensitive areas (e.g. face).
In the first weeks, use together with topical corticosteroids or as a fixed combination is superior to monotherapy with respect to efficacy and tolerance.
For moderate to severe psoriasis vulgaris, a combination of topical vitamin D 3 -analogues with UV phototherapy or a systemic therapy can be recommended. 
Phototherapy
Instructions for application
Pre-treatment
The attending physician has to perform a complete skin examination, paying special attention to melanocytic nevi (especially if dysplastic) and cutaneous malignancies. The patient has to be informed about unwanted side effects and possible long-term risks -especially the therapy-related increased risk of skin cancer. Additional UV exposure as a result of leisure-time activities should be considered. Written informed consent must be obtained. Before starting oral PUVA therapy, an ophthalmologic examination and the prescription of UV sunglasses is required.
During treatment
The UV dosages applied must be documented in precise physical units (J/cm 2 or mJ/cm 2 ). Regular monitoring of UV erythema must be performed for the purpose of dosage increase. The medical records should document therapeutic response, unwanted side effects, and accompanying treatments. Eye protection with UV glasses is generally required. If the areas chronically exposed to light (face, neck, backs of hands) and the genital region are free of lesions, these should be protected from exposure. Adequate protection from the sun must accompany therapy.
Post-treatment
Whenever a course of therapy is completed, the cumulative UV dosage and the number of treatments should be recorded and the patient has to be informed. Particularly in the case of patients with high cumulative UV dosage, a regular skin cancer examination should be performed for the patient's entire life.
General assessment
Of the 145 studies on monotherapy or combination therapy assessed, 25 studies on phototherapy, 32 studies on PUVA therapy, and five studies on therapeutic procedures with lasers fulfilled the Guidelines' inclusion criteria. [37] [38] [39] [40] About three-quarters of all the patients treated with phototherapy attained at least a 75% PASI score reduction after 4-6 weeks, and clearance was frequently achieved (LE 2). Phototherapy represents a safe and very effective modality for the treatment of moderate to severe forms of psoriasis vulgaris. The onset of the clinical effects is within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term application, the consequences of high, cumulative UV dosages (i.e. premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicality of the therapy is limited as a result of the spatial, financial, and human aspects as well as by time resources on the part of the physician as well as the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs and time required of the patient must be noted.
Therapeutic recommendation
Phototherapy is recommended as an induction therapy for moderate to severe psoriasis vulgaris, above all for widespread involvement.
The side effects of specific types of radiation must be weighed. A possible subsequent risk of skin cancer is better documented for PUVA than for UVB.
Due to its low practicality and the association of longterm unwanted side effects with the cumulative UV doses, phototherapy is not suitable for long-term treatment.
Combination with topical vitamin D 3 -analogues is recommended to improve the response rate.
A recommendation for the common combination with dithranol and corticosteroids can only be given on the basis of clinical experience, but not on the basis of scientific data.
The use of Excimer Lasers should be limited to the targeted treatment of individual psoriatic plaques. Table 3 .5.1.1.2)
Arch Dermatol
Res (2007) 299:111-138 121 Evaluation of systemic therapies Efalizumab
Post-treatment
Patients, who discontinue efalizumab should be subject to close follow-up. In cases of reoccurrence or exacerbation of the disease, the introduction of another suitable psoriasis treatment is recommended.
Patients should be informed about the possibility of the occurrence of a rebound, which would make an immediate consultation necessary. Table 9 Laboratory controls during treatment with efalizumab
---------------------------------------------------------------------------------------------------------------------------
Period in months Diagnostics Before 1 2 3 4 5 6 9
a Hb (hemoglobin), HCT (hematocrit), erythrocytes, leukocytes, differential blood count, platelets b ALT alanine aminotransferase, AST aspartate aminotransferase
General assessment
All six of the studies assessed in terms of the efficacy of therapy with efalizumab fulfilled the Guidelines' inclusion criteria. [101] [102] [103] [104] [105] [106] Approximately 30 and 40% of those patients with moderate to severe psoriasis vulgaris treated with efalizumab at a dose of 1 mg/kg BW per week attained a PASI reduction of > 75% (LE 1) within 12 weeks and 24 weeks, respectively. As a result of the only once-per-week subcutaneous injection and the only rarely required medical controls, the therapy is highly practicable for both the patient and the attending physician. Based on current knowledge, efalizumab possesses a favorable safety profile. A follow-up of a larger patient population for a longer period of time is necessary for a definitive assessment of the efficacy and safety as a long-term treatment.
Compared to other biologics, experience with efalizumab is significantly lower due to the smaller patient populations which have been treated with efalizumab. Disease exacerbation during therapy or a rebound after therapy has been observed.
Therapeutic recommendation
Efalizumab is recommended for induction therapy of moderate to severe psoriasis vulgaris especially if other therapeutic options have not demonstrated sufficient therapeutic effect, are not tolerated, or are contraindicated.
Therapy should not be continued if an improvement of at least 50% of the initial findings is not observed after the first 12 weeks of treatment. Other -
Etanercept
Instructions for application
Pre-treatment Exclusion of acute and chronic infections, absolute exclusion of tuberculosis in accordance with the current recommendations of the Paul Ehrlich Institute (www.pei.de) Reliable contraception and exclusion of pregnancy in women of childbearing age Patients should be informed about the risk of severe infections. Hand out user information and special comment card to patients
During treatment
Monitoring during infusion and 1-2 hours thereafter Monitoring for infections; the therapy should at least be temporarily discontinued when an infection is suspected
Post-treatment
In women of childbearing age, contraception for up to 6 months after infliximab therapy 
---------------------------------------------------------------------------------------------------------------------------
Diff. Blood count x x x x x -
--------------------------------------------------------------------------------------------------------------------------ALT, AST x x x x x ---------------------------------------------------------------------------------------------------------------------------Pregnancy test x (urine)
General assessment
Of the four studies assessed, three fulfill the Guidelines' inclusion criteria. [107] [108] [109] During etanercept therapy, approximately 35% of the patients attained a PASI reduction of 75% after 12 weeks with two subcutaneous doses of 25 mg per week. With a therapy with 2× 50 mg subcutaneous per week for 12 weeks approximately 50% of the patients attained a PASI reduction of 75% (LE 1). Clinical experience has shown that clinical efficacy can be maintained in a long-term therapy for up to 24 weeks. The therapy is practicable for both the patient and the physician. As a result of the large number of patients treated with etanercept for other indications, the risk of adverse drug reactions can be estimated very well.
Therapeutic recommendation
Etanercept is recommended for induction therapy for patients with moderate to severe psoriasis vulgaris, especially if other therapeutic options have not demonstrated satisfactory therapeutic success, are not tolerated, or are contraindicated.
If concomitant psoriasis vulgaris and relevant psoriasis arthritis are present, treatment with TNF-alpha antagonists is particularly recommended. Reduced renal function, insufficiently controlled arterial hypertension, uncontrolled infections, relevant malignancies (current or previous, in particular hematologic diseases and cutaneous malignancies with the exception of basal cell carcinoma) Relative:
Cyclosporine
Relevant hepatic dysfunction, pregnancy and nursing, concomitant use of substance which interacts with cyclosporine, concomitant UVtherapy or prior PUVA-pre-therapy with cumulative dosage >1000 J/ cm 2 , concomitant application of other immunosuppressives, retinoids or long-term prior-therapy with methotrexate (MTX)
General assessment
Of the seven studies evaluated, four fulfill the Guidelines' inclusion criteria. [110] [111] [112] [113] Approximately 88% of the patients with moderate to severe psoriasis showed a PASI reduction of 75% after 10 weeks infliximab treatment with a dose of 5 mg/kg BW in the normal therapy intervals (LE 1). Infliximab is currently one of the most effective drugs for the treatment of psoriasis vulgaris. On the basis of the data available from long-term studies, good efficacy is also expected in the long-term therapy of psoriasis vulgaris. A number of safety aspects should be considered with infliximab. Amongst these are, above all, infusion reactions and the risk of severe infection. This requires a careful evaluation of the indication, education, as well as monitoring of the patient. As a result of the large number of patients treated with infliximab for other indications, the risk of adverse drug reactions can be estimated very well.
Therapeutic recommendation
Infliximab is recommended for the induction therapy of moderate to severe psoriasis vulgaris and severe, special forms of psoriasis which cannot be controlled by other therapeutic options or if, on the basis of the severity of the disease, a rapid resolution is required.
If concomitant psoriasis vulgaris and relevant psoriasis arthritis are present, treatment with TNF-alpha antagonists is particularly recommended. ------------------------------------------------------------------------------------------------------------------------- 
infusion ---------------------------------------------------------------------------------------------------------------------------AST, ALT x Prior to start of therapy and before every infusion ---------------------------------------------------------------------------------------------------------------------------
General assessment
Of 65 studies evaluated with respect to the efficacy of a cyclosporine monotherapy in psoriasis, 15 studies fulfilled the Guidelines' inclusion criteria. [86, [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] Cyclosporine demonstrated a high effectiveness in the therapy of adults in these clinical studies. After 12-16 weeks, 50-70% of the patients achieved a PASI 75 (LE 1). Cyclosporine is primarily suited for induction therapy; in long-term therapy a careful and individual weighing of the risks and benefits must be performed due to the adverse drug reactions, especially the nephrotoxicity and increase in blood pressure as well as the possibility of an increased risk of malignancies. With the application of cyclosporine, a variety of drug reactions need to be considered, which on the one hand lead to a change in the availability of cyclosporine or concomitant medications, and on the other hand might increase the risk of adverse drug reactions. As a result of its long-term use for various indications, including psoriasis vulgaris, an extensive body of data is available -also in terms of safety during long-term therapy with cyclosporine. Cyclosporine represents an effective therapy for moderate and severe psoriasis vulgaris.
Therapeutic recommendation
Cyclosporine is primarily recommended for induction therapy for moderate to severe psoriasis vulgaris in adults who cannot be sufficiently treated with a topical therapy and/or phototherapy. In these cases, there is an acceptable risk-benefit ratio.
Cyclosporine can also be used for the long-term therapy of suitable patients over a period of up to 2 years maximum, whereby an increasing toxicity and a decreasing efficacy should be considered.
A combination with topical preparations for the treatment of psoriasis vulgaris is possible and reasonable, especially because there are signs that combining cyclosporine with topical vitamin D 3 -analogues or corticosteroids may allow a dose reduction of cyclosporine without a loss of efficacy. ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- 
Instructions for application
Pre-treatment Laboratory controls (see Table 3 .5.3.3)
During treatment
Laboratory controls (see Table 3 .5.3.3)
Post-treatment
None
General assessment
Of 13 studies evaluated, nine fulfilled the Guidelines' inclusion criteria. [128] [129] [130] [131] [132] [133] [134] [135] [136] After 16 weeks, 50-70% of the patients had a PASI 75 (LE 2). There was good efficacy in the induction therapy and in the longterm therapy. The therapy of psoriasis vulgaris with fumaric acid esters represents an effective systemic treatment which demonstrates a high level of long-term safety. The tolerance is limited by adverse gastrointestinal drug reactions and flush symptoms. The risk-benefit analysis of fumaric acid esters is positive, the practicality for both patients and physicians is good, and the costbenefit ratio is acceptable. Positive aspects of the therapy with fumaric acid esters are the low number of drug interactions, the lack of immunosuppressive effects, the absence of increased susceptibility to infection, and the absence of any risk of malignancies during the long-term therapy. A combination with topical medications for the treatment of psoriasis vulgaris is recommendable.
Therapeutic recommendation
Treatment with fumaric acid esters is recommended as an effective induction therapy for moderate to severe psoriasis vulgaris in adults.
Their application is primarily limited by gastrointestinal ADRs. A combination with any topical drugs for the treatment of psoriasis vulgaris is possible and reasonable.
Because of the favorable risk-benefit profile with good tolerability during long-term therapy, fumaric acid esters are highly recommended. Table 3 .5.4.2) With dosage increases and an increased risk of an elevated MTX concentration (dehydration, reduced renal function, new medications) controls are performed more frequently An assay of type III procollagen amino terminal propeptide (PIIINP) in serum is recommended Liver biopsy: as soon as there is a longer treatment period following a cumulative dose of more than 1.5 g or more or if liver damage is suspected, a hepatologist should be consulted to determine whether a liver biopsy is needed [73, 76] Chest x-ray: for complaints such as fever, coughing, dyspnoea, and cyanosis; important: MTX pneumonitis For the general reduction of toxicity, 5 mg per day folic acid can be recommended on the days when there is no MTX intake Careful registration of cumulative dose
weeks -------------------------------------------------------------------------------------------------------------------------------
Complete blood count a x x x --------------------------------------------------------------------------------------------------------------------------- ALT, AST,γ GT x x x --------------------------------------------------------------------------------------------------------------------------- Serum creatinine x x x --------------------------------------------------------------------------------------------------------------------------- Urinanalysis x x x Methotrexate
Post-treatment
Reliable contraceptive measures for at least 3 months after therapy in both men and women
General assessment
Of 11 MTX monotherapy studies assessed for efficacy in psoriasis vulgaris, three studies fulfilled the Guidelines' inclusion criteria. [123, 138, 139] . After a 16-week therapy with MTX, approximately 60-75% of the patients displayed a 75% reduction of the PASI score (LE 3). Clinical experience with MTX is much greater than the documentation of the efficacy and safety of a MTX therapy in clinical studies. Clinical experience has demonstrated that with longer treatment, the efficacy continues to increase and MTX therefore represents, above all, an effective therapeutic option for long-term therapy. The clinical application is restricted by severe ADRs including, in particular, hepatotoxicity, nephrotoxicity, bone marrow suppression, gastrointestinal ulcerations and very rare, but severe idiosyncratic reactions. With precise patient selection, thorough patient information, strict monitoring, administration of the lowest effective dosage (max. 22.5 mg per week) and the additional administration of folic acid or folinic acid, an acceptable safety profile can also be attained for MTX therapy. MTX provides the lowest drug costs per day of all the systemic therapeutics.
Therapeutic recommendation
MTX is effective in the treatment of moderate to severe psoriasis vulgaris; its use is limited by the contraindications and numerous controls needed during therapy.
MTX is, as a result of its slow onset of action, less recommendable for short-term induction therapy than for long-term therapy. -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------Liver sonography c  x  -------------------------------------------------------------------------------------------------------------------------- Chest X-ray x  ---------------------------------------------------------------------------------------------------------------------------Hepatitis B, C serology  x  ------------------------------------------------------------------------------------------------------------------------- 
Instructions for application
Pre-treatment Anamnesis Exclusion of pregnancy/nursing a (patient must be informed expressly and extensively about the teratogenic risk of the medication, the necessity of effective and long-term contraception, and the possible consequences of a pregnancy while taking retinoids); written documentation of the patient information interview Alcohol consumption (women of child-bearing age may not drink alcohol during and up to 2 months after treatment with acitretin) Exclusion of alcohol abuse Question regarding bone aches and aches in joints Laboratory controls (see Table 3 .5.5.2)
During treatment
With long-term treatment (approximately 1-2 years): radiological control examinations of the spine and joints are recommended if signs and symptoms develop to exclude possible occurrence of ossification Reliable contraception a in women of child-bearing age For women of child-bearing age: No alcohol consumption during therapy Laboratory controls (see Table 3 .5.5.2)
Post-treatment
Patients may not donate blood for up to 1 year after the discontinuation of therapy Reliable contraception a in women of child-bearing age up to 2 years after therapy For women of child-bearing age: no alcohol consumption up to 2 months after end of therapy a Double contraception is recommended (e.g., condom + pill; IUD/Nuva-Ring + pill; cave: no low-dosed progesterone preparations/mini-pills) during and up to 2 years after the end of therapy; effectiveness is reduced by acitretin
General assessment
Of 52 studies assessed, four fulfilled the Guidelines' inclusion criteria in terms of a monotherapy and another four in terms of a combination therapy. [91] [92] [93] [140] [141] [142] [143] As a result of the very heterogeneous study results, it is not possible to make a clear statement regarding the efficacy of a monotherapy with acitretin (LE 3). The effectiveness of retinoids in lower dosages as a monotherapy in moderate to severe psoriasis vulgaris is not satisfactory. Higher dosages result in an increase of the efficacy, but these are frequently accompanied by increased ADRs in the skin and mucous membranes. In women of childbearing age, the teratogenity, the monthly pregnancy tests, and the need for contraception for up to 2 years after the termination of the therapy severely limit the use of acitretin. An advantage of treatment with retinoids is the synergistic effect in combination with UV light. There is, however, insufficient evidence available on the basis of the studies included to recommend this approach.
Therapeutic recommendation
Acitretin is not recommended as a monotherapy because of lack of efficacy.
The application of higher dosages, which are more effective, is limited because of frequent adverse drug reactions.
The treatment of plaque psoriasis with acitretin in women of child-bearing age is strongly discouraged. 
Other therapies
Climate/balneotherapy
General assessment
Of 33 studies assessed, three fulfilled the Guidelines' inclusion criteria. [144] [145] [146] . This translates into a level of evidence 4. The onset of clinical effect and the response rate vary greatly. For that reason, it is not possible to provide exact figures. Balneotherapy and climate therapy have been successfully applied for the treatment of psoriasis vulgaris for centuries and are frequently used in combination with other therapies. These are treatment modalities which have been developed over the years, but for which only very preliminary scientific data are available. In the case of a combined strategy using natural phototherapeutic principles, efficacy and safety are similar to those of simple phototherapy. Balneotherapy and climate therapy are tied to certain geographic regions and the specialized facilities located there.
Therapeutic recommendation
Balneotherapy and climate therapy have a special place in the framework of the long-term management of psoriasis vulgaris.
The integration of appropriate therapy phases into the treatment concept of patients with psoriasis vulgaris requiring treatment for years can be recommended.
These methods are not indicated for acute treatment or short-term therapy. -------------------------------------------------------------------------------------------------------------------------- 
--------------------------------------------------------------------------------------------------------------------------AST, ALT, AP, yGT x x x x ---------------------------------------------------------------------------------------------------------------------------Creatinine, urea x ---------------------------------------------------------------------------------------------------------------------------Triglycerides, cholesterol, HDL b x x x ---------------------------------------------------------------------------------------------------------------------------
Pregnancy test (urine) (monthly up to 2 years after therapy)
x Monthly  ------------------------------------------------------------------------------------------------------------------------- 
Psychosocial therapy
General assessment
Of eight studies evaluated, three fulfilled the Guidelines' inclusion criteria. [77, 147, 148] This resulted in a level of evidence 4. These studies of an additive, psychosocial treatment of psoriasis patients with the evidence grade B or C and with a large random sample selection as well as a relatively large dropout rates do not allow for any final conclusions to be drawn with respect to the efficacy of these therapies. The low number of adverse events is certainly an advantage. With a psychosocial treatment like Psoriasis Symptom Management or patient training, direct effects on skin symptoms can be achieved through, for example, improved stress management, and indirect effects on the development of the psoriasis can be achieved through, for example, improved compliance. These two forms of therapy should be further investigated empirically.
Therapeutic recommendation
The possible impacts of the disease on social, emotional and psychic aspects should be considered for every psoriatic patient.
Information on existing self-help groups is recommended.
The possibility of participating in a structured training program in accordance with the recommendations of the ADP (Arbeitsgemeinschaft Dermatologische Präven-tion) of the DDG should be pointed out.
If the suffering is very intense or in cases of repeated clear exacerbation of the psoriasis vulgaris with stress, evaluation by an appropriate specialist with training in psychosomatics or psychotherapy can be offered if the patient so desires and, if necessary, psychosocial therapy initiated.
Notes on the use of the Guidelines
The presentation of the therapies deliberately focused on those aspects deemed particularly relevant by a panel of experts. Aspects which are not of specific importance for a certain intervention, but which are part of the physician's general obligations to the patient, such as the investigation of intolerance and allergies toward certain drugs or the exclusion of contraindications, are not individually listed, but it is nevertheless taken for granted that these are part of the physician's duty to provide care.
It is recommended that each and every user carefully reads and follows the product information and compare it with the recommendations in the Guidelines on dosaging, contraindications, and drug interactions for completeness and currentness. Every dose or application is administered at the user's own risk. The authors and the publishers kindly request that users inform them of any inaccuracies that they might notice. The users are requested to keep themselves constantly informed of any new findings subsequent to the publication of the Guidelines.
